We are delighted to announce Friedmund Bachmann’s well-deserved promotion to the role of Vice President CMC at OncoOne, effective April 1, 2023!

With a remarkable career spanning renowned companies such as Baxter, Baxalta, Shire, and Takeda, Friedmund has gathered a wealth of experience and held positions of increasing responsibility in Pharmaceutical Sciences, CMC Development, and CMC Operations. Friedmund’s successful leadership of CMC programs throughout the product life cycle highlights his profound understanding of the value chain for biological products, particularly in the fields of vaccines, oncology, hematology, and inflammatory diseases.

Since joining OncoOne in 2021 as Director CMC, Friedmund has been instrumental in our growth and success. Leading our CMC development and the PreTarg-It® program, his passion for innovation and unwavering dedication have delivered outstanding results. We’re thrilled to have Friedmund in his elevated role, driving our mission to provide innovative therapies for cancer and inflammatory disorders.

Congratulations to Friedmund on this well-deserved promotion! His inspiring contributions and commitment make him a valuable asset to OncoOne. We can’t wait to see the impact he’ll continue to make in his new role. Wishing you continued success, Friedmund!

Please join us in congratulating Friedmund and wishing him continued success in his new role!